Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

A vanishing act: the incredible erlotinib.

Arora S, Sawhney H.

J Cancer Res Ther. 2012 Jul-Sep;8(3):464. doi: 10.4103/0973-1482.103539. No abstract available.

PMID:
23174741
[PubMed - indexed for MEDLINE]
Free Article
2.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
[PubMed - indexed for MEDLINE]
Free Article
3.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
[PubMed - indexed for MEDLINE]
4.

Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.

Yanagisawa S, Morikawa N, Kimura Y, Nagano Y, Murakami K, Tabata T.

Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x. No abstract available.

PMID:
22943430
[PubMed - indexed for MEDLINE]
Free Article
5.

XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.

Pietanza MC, Lynch TJ Jr, Lara PN Jr, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, Mitchell B, Wakelee HA, Miller VA.

J Thorac Oncol. 2012 Jan;7(1):219-26. doi: 10.1097/JTO.0b013e31822eebf9.

PMID:
22011666
[PubMed - indexed for MEDLINE]
6.

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.

van Riel S, Thunnissen E, Heideman D, Smit EF, Biesma B.

Ann Oncol. 2012 Dec;23(12):3188-9. doi: 10.1093/annonc/mds525. Epub 2012 Oct 18. No abstract available.

PMID:
23079729
[PubMed - indexed for MEDLINE]
Free Article
7.

From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.

Mazzoni F, Rotella V, Pratesi N, Boni L, Simi L, Orlando C, Comin CE, Maddau C, Di Costanzo F.

Tumori. 2011 Mar-Apr;97(2):160-5. doi: 10.1700/667.7777.

PMID:
21617709
[PubMed - indexed for MEDLINE]
8.

Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2011 Mar;25(6):1-5. No abstract available.

PMID:
21638942
[PubMed - indexed for MEDLINE]
9.

Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.

Cho D, Kocher O, Lee JC, Tenen DG, Meyerson ML, Janne PA, Halmos B.

J Clin Oncol. 2005 Jan 1;23(1):235-7. No abstract available. Erratum in: J Clin Oncol. 2005 Apr 1;23(10):2444.

PMID:
15625379
[PubMed - indexed for MEDLINE]
10.

Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.

Ludovini V, Gori S, Pistola L, Della Fazia MA, Piobbico D, Servillo G, Flacco A, Scuderi C, Crinò L.

J Thorac Oncol. 2008 Apr;3(4):452-3. doi: 10.1097/JTO.0b013e318169e341. No abstract available.

PMID:
18379371
[PubMed - indexed for MEDLINE]
11.

Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.

Zorzou MP, Stratigos A, Efstathiou E, Bamias A.

Acta Derm Venereol. 2004;84(4):308-9. No abstract available.

PMID:
15339078
[PubMed - indexed for MEDLINE]
12.

EGFR mutations and sensitivity to gefitinib.

Rich JN, Rasheed BK, Yan H.

N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1. No abstract available.

PMID:
15376352
[PubMed - indexed for MEDLINE]
13.

Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.

Saijo N.

Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168. No abstract available.

PMID:
20981125
[PubMed - indexed for MEDLINE]
14.

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.

Popat S, Vieira de Araújo A, Min T, Swansbury J, Dainton M, Wotherspoon A, Lim E, Nicholson AG, O'Brien ME.

J Thorac Oncol. 2011 Nov;6(11):1962-3. doi: 10.1097/JTO.0b013e31822eec5e. No abstract available.

PMID:
22005476
[PubMed - indexed for MEDLINE]
15.

EGFR mutations and sensitivity to gefitinib.

Rossi G, Marchioni A, Longo L.

N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1. No abstract available.

PMID:
15376351
[PubMed - indexed for MEDLINE]
16.

Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.

Friedrich MJ.

J Natl Cancer Inst. 2009 Aug 5;101(15):1039-41. doi: 10.1093/jnci/djp243. Epub 2009 Jul 28. No abstract available.

PMID:
19638503
[PubMed - indexed for MEDLINE]
Free Article
17.

Epidermal growth factor receptor mutations: a new insight.

Belani CP.

Clin Lung Cancer. 2004 May;5(6):328. No abstract available.

PMID:
15217529
[PubMed - indexed for MEDLINE]
18.

Targeting targeted therapy.

Green MR.

N Engl J Med. 2004 May 20;350(21):2191-3. Epub 2004 Apr 29. No abstract available.

PMID:
15118072
[PubMed - indexed for MEDLINE]
Free Article
19.

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C.

Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.

PMID:
21783417
[PubMed - indexed for MEDLINE]
20.

Role of tyrosine kinase inhibitors in lung cancer.

Ansari J, Palmer DH, Rea DW, Hussain SA.

Anticancer Agents Med Chem. 2009 Jun;9(5):569-75.

PMID:
19519298
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk